FRI AM News: WisBusiness: the Podcast with Serafino Fabiano, Eli Lilly and Company; State joins lawsuit targeting Trump administration over family planning funding

Eli Lilly's Mounjaro (tirzepatide) received FDA approval to reduce cardiovascular risk in type 2 diabetes patients. The approval follows positive results from the SURPASS-CVOT trial, showing an 8% lower rate of major adverse cardiovascular events compared to Trulicity. Mounjaro is the first GIP and GLP-1 receptor agonist with this indication, according to the company.

Eli Lilly's Mounjaro (tirzepatide) received FDA approval to reduce cardiovascular risk in adults with type 2 diabetes. The approval follows a trial showing an 8% lower rate of cardiovascular events compared to Trulicity (dulaglutide). Mounjaro is already approved for blood sugar control and is the top-prescribed branded diabetes medicine in the U.S.

The FDA cleared a new blood test, Elecsys pTau217, developed by Roche and Eli Lilly, for evaluating Alzheimer's disease in people 55+. The test measures phosphorylated tau 217, a biomarker linked to amyloid pathology. It is designed to support diagnostic assessments but not replace full medical evaluations. Roche and Lilly aim to make the test accessible in primary care settings, potentially improving early diagnosis and treatment planning.

Eli Lilly's (LLY) stock rose 78.5% over the past year, driven by volume growth despite a 3% U.S. price decline in Q2 2026. Mounjaro and Zepbound contributed $14.9B in revenue. The company plans to expand access to its drugs, which may lower prices but is expected to be offset by volume growth. Operating margin is 49.7% over the past year.

Eli Lilly and Company's Serafino Fabiano discusses a $4 billion investment in Wisconsin for injectable medicine production, including Zepbound and Mounjaro. The Kenosha facility, acquired in 2024, is creating 750 jobs and supports local contractors. Fabiano highlights the strategic location and skilled workforce, with the company committing over $50 billion since 2020 to global manufacturing expansion.

On August 24, 2026, the FDA cleared a new blood test, Elecsys pTau217, developed by Roche and Eli Lilly, to detect Alzheimer’s disease in adults 55+ with cognitive decline. The test measures pTau217 levels, aiding both rule-in and rule-out assessments of amyloid pathology. Experts highlight its simplicity, accuracy, and potential to improve diagnostic access.